Professor Chen Yanming: Prevention and Treatment Strategies for Diabetic Retinopathy

Professor Chen Yanming from the Third Affiliated Hospital of Sun Yat-sen University delivered an in-depth presentation on the theme Early Pathological Changes in Diabetic Retinopathy: Metabolic Damage. His insights on the prevention and treatment strategies for diabetic retinopathy (DR) are summarized as follows:Classic clinical trials (DCCT, UKPDS, ADVANCE, VADT) have all demonstrated that intensive glycemic […]

Professor Chen Yanming: Multi-Omics-Based Prediction and AI-Powered Precision Diagnosis of DR

At the 27th Annual Conference of the Chinese Society of Diabetes (CDS 2025), Professor Chen Yanming from the Third Affiliated Hospital of Sun Yat-Sen University delivered a presentation on multi-omics-based prediction and AI-powered precision diagnosis of diabetic retinopathy (DR).Multi-Omics-Based Prediction and AI-Powered Precision Diagnosis of DRThe application of multi-omics technologies — including genomics, epigenomics, transcriptomics, […]

Professor Chen Yanming: Metabolic Damage Dominates Early-Stage Diabetic Retinopathy

Diabetic retinopathy (DR) is one of the leading causes of blindness among the working-age population worldwide. Traditionally regarded as a typical microvascular disease, a growing body of research clearly demonstrates that retinal metabolic damage is not a passive accompaniment but a causal origin driving neurovascular destruction.At the 27th Annual Conference of the Chinese Society of […]

Substantial Progress Made in Innovative Treatments for Diabetic Retinopathy

Substantial and ongoing advances have been achieved in innovative therapeutic approaches for diabetic retinopathy (DR).The latest breakthroughs are highlighted in the following areas:Nano-Drug Delivery Technologies Break Through the Blood-Retinal BarrierTargeting the pain point of repeated intravitreal injections required by traditional anti-VEGF drugs,nano-drug delivery systems have achieved critical breakthroughs.The TAT-iRGD dual-targeting nano eye drops developed by […]

Innovations in Diabetic Retinopathy Treatment Strategies: Diversified Targets and Long‑Acting Drug Delivery

In recent years, pharmacotherapy for diabetic retinopathy (DR) has gradually shifted from traditional single‑target anti‑VEGF intervention to multi‑pathway coordinated regulation.Evidence‑based medical data for the bispecific antibody faricimab (Ang‑2/VEGF‑A dual inhibitor) in DR treatment continues to accumulate.Post hoc analyses of the YOSEMITE/RHINE trials revealed that faricimab significantly enhances vascular stability compared with aflibercept, and the injection […]

Basic Research on Diabetic Retinopathy Establishes Core Evidence for Precision Diagnosis and Treatment

Basic research on diabetic retinopathy (DR) in 2025 focused on the dissection of pathological networks, biomarker discovery, and therapeutic target development, achieving multi‑dimensional breakthroughs covering immunity, metabolism, and the gut‑eye axis, and laying core evidence for precision diagnosis and treatment.In terms of pathogenic mechanism networks:Studies revealed that high glucose drives angiogenesis via the perlecan‑HIF‑1α axis […]

AI and Big Data as Enabling Technologies for Diabetic Retinopathy Screening

AI and big data have become enabling technologies for diabetic retinopathy (DR) screening.Diabetic retinopathy is the most common microvascular complication of diabetes and the leading cause of blindness among the working‑age population worldwide.With population aging and the rising prevalence of diabetes, the situation for DR prevention and treatment has become increasingly severe.AI and big data […]

Symptoms, Staging and Diagnosis of Diabetic Retinopathy

Diabetic retinopathy is a common microvascular complication of diabetes. Typical symptoms include decreased vision, distorted vision, and irreversible blindness. Its pathological features are microaneurysms, hemorrhage, exudation and neovascularization. Long-term hyperglycemia is the main inducement, and patients with poor glycemic control are more susceptible. Other risk factors include hypertension, hyperlipidemia, long duration of diabetes, pregnancy, etc. […]